A study into efficacy of omalizumab therapy in patients with severe persistent allergic asthma at a tertiary referral centre for asthma in Ireland

Subramaniam, Abirami; Al‐Alawi, Mazen; Hamad, S.; O’Callaghan, J.R.; Lane, Stephen

doi:10.1093/qjmed/hct072

Cited by 15 publications

(14 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To minimize bias, non-significant results reported in the original publication were included in our pooled estimates. Table 1 summarizes the 42 studies stratified by 30 adult-only studies [24,26,27,[30][31][32][33][34][35][36][37][40][41][42][43][44][45][46][47][58][59][60][61][62][63][64][65][66][67][68] (n = 3558) and 12 adult/ adolescent studies [25,38,39,56,57,[69][70][71][72][73][74][75][76][77] (n = 5819). These 42 studies comprised a total of 9377 patients from 35 countries: 25 in Europe (incl.…”

Section: Other Methodological Considerationsmentioning

confidence: 99%

Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018

MacDonald

Kavati

Ortiz

et al. 2019

Expert Review of Clinical Immunology

View full text Add to dashboard Cite

Introduction: Omalizumab is a recombinant monoclonal anti-IgE antibody approved in the US as add-on treatment in moderate-to-severe allergic asthma (in severe allergic asthma [SAA] in Europe). A 2016 review of 24 real-world effectiveness studies in SAA published between 2008-2015 concluded that omalizumab was associated with significant improvements in objective and subjective outcomes with benefits extending beyond 2 years. Several new real-world studies have been published since, bringing the total to 42 studies. Areas covered: This systematic review of 42 studies published since 2008 updates and extends the 2016 review on the real-word evidence on omalizumab in SAA. It offers greater granularity as to time windows within which outcomes are reported and includes studies extending well beyond 4 years post omalizumab initiation. Expert commentary: This review firmly establishes the short-term effectiveness of omalizumab in adolescent and adult patients with SAA at 1 year, and provides strong evidence of long-term effectiveness up to 4 years and emergent evidence of effectiveness beyond 4 years. In the aggregate, these 42 studies underscore the long-term effectiveness of omalizumab in terms of: reducing exacerbations and symptoms, achieving asthma control, improving lung function, enhancing quality of life, decreasing emergency department visits and hospitalizations, and promoting concomitant medication-sparing. ARTICLE HISTORY

show abstract

Section: Other Methodological Considerationsmentioning

confidence: 99%

Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018

MacDonald

Kavati

Ortiz

et al. 2019

Expert Review of Clinical Immunology

View full text Add to dashboard Cite

show abstract

“…Other anti-asthmatic treatments, both prior to and after start of omalizumab treatment, were included in twelve of these studies (28, 30-33, 35, 37, 42, 44, 45, 48, 49). The most common clinical outcome, included in 14 studies, was FEV1 (28,32,34,35,37,39,42,43,(45)(46)(47)(48)(49)(50). Fewer studies reported on other objective (32,34,39,46,49,50) and subjective (29,41) (37,42,50)), and work or school days lost due to asthma (29,32,37,44).…”

Section: Study Designsmentioning

confidence: 99%

“…Hence, the majority of patients can be estimated to have ranged from about 25 to 70 years of age -covering the predominant adult population. There was a slight preponderance of female patients: there were proportionately more women in 20 of the 23 studies reporting gender distribution (27)(28)(29)(30)(31)(32)(33)(34)(35)(37)(38)(39)(40)(41)(42)(43)(44)(45)(46)(47)(48)(49)(50). The majority of patients weighed between 66 kg (44) and 81 kg (45) Omalizumab candidates presented with marked one-year histories of severe exacerbations.…”

Section: Patientsmentioning

confidence: 99%

See 1 more Smart Citation

‘Real-life’ effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review

Abraham

Alhossan

Lee

et al. 2016

Allergy

112

View full text Add to dashboard Cite

We reviewed 24 'real-life' effectiveness studies of omalizumab in the treatment of severe allergic asthma that included 4117 unique patients from 32 countries with significant heterogeneity in patients, clinicians and settings. The evidence underscores the short-and long-term benefit of anti-IgE therapy in terms of the following: improving lung function; achieving asthma control and reducing symptomatology, severe exacerbations and associated work/school days lost; reducing healthcare resource utilizations, in particular hospitalizations, hospital lengths of stay and accident specialist or emergency department visits; reducing or discontinuing other asthma medications; and improving quality of life -thus confirming, complementing and extending evidence from randomized trials. Thus, omalizumab therapy is associated with signal improvements across the full objective and subjective burden of illness chain of severe allergic asthma. Benefits of omalizumab may extend up to 2-4 years, and the majority of omalizumab-treated patients may benefit for many years. Omalizumab has positive short-and longterm safety profiles similar to what is known from randomized clinical trials. Initiated patients should be monitored for treatment response at 16 weeks. Those showing positive response at that time are highly likely to show sustained treatment response and benefit in terms of clinical, quality of life and health resource utilization outcomes.Over the past four decades, the prevalence, morbidity and mortality of asthma have increased significantly (1-4). In particular, severe asthma, which affects about 10% of all patients with asthma, presents with significant morbidity, high healthcare resource utilization and impaired quality of life (5). As there is no cure for asthma, the objective of treatment is to control the clinical aspects of the disease (6). Despite guidelines for the evaluation, classification and management of asthma, most patients and certainly those with severe asthma are controlled suboptimally (7-10).Immunoglobulin E (IgE) is an antibody class associated with hypersensitivity and allergic reactions (11). IgE elicits an immune response by binding mainly to the high-affinity receptor (FceRI) found on the surface of mast cells and basophils. In the mast cell, activation of these receptors through cross-linking with IgE causes the cell to release inflammatory mediators (11).Omalizumab (Xolair Ò , Novartis basel, Switzerland) is a recombinant humanized monoclonal anti-IgE antibody that inhibits the binding of IgE to high-affinity receptors. It is indicated as add-on treatment to inhaled corticosteroids (ICS) and long-acting b2-agonists (LABA). Initial treatment response is evaluated at 16 weeks, and treatment is continued in patients showing a response at that time. Phase III trials with study periods up to 12 months have shown omalizumab to reduce the frequency of asthma exacerbations and concomitant medication burden and improve symptom severity and quality of life, while also being safe (12-15). Effica...

show abstract

“…Our SLR identified 83 primary studies with epidemiology data relevant to SUA; all were observational studies. Three studies were international (involving multiple countries from different continents) [11][12][13] , and the remaining studies were from Asia [14][15][16][17][18][19] , Australia 20,21 , Germany 22,23 , France [24][25][26][27] , Italy [28][29][30][31][32][33][34][35] , Spain 36-40 , the UK 6,[41][42][43][44][45][46][47][48] , Europe (other) [49][50][51][52][53][54][55][56][57][58][59][60][61][62][63][64]…”

Section: Epidemiology Of Asthma Uncontrolled By Gina Steps 4 or 5 Trementioning

confidence: 99%

Systematic literature review of the clinical, humanistic, and economic burden associated with asthma uncontrolled by GINA Steps 4 or 5 treatment

Chen

Golam

Myers

et al. 2018

Current Medical Research and Opinion

View full text Add to dashboard Cite

show abstract

A study into efficacy of omalizumab therapy in patients with severe persistent allergic asthma at a tertiary referral centre for asthma in Ireland

Cited by 15 publications

References 12 publications

Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018

Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018

‘Real-life’ effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review

Systematic literature review of the clinical, humanistic, and economic burden associated with asthma uncontrolled by GINA Steps 4 or 5 treatment

Contact Info

Product

Resources

About